risk, though a role for omega-3 supplementation in treatment of depression is still controversial.33 Variants in SPPL3, encoding “Signal Peptide Peptidase Like 3”, were reported to be associated with risk to major depression by Hyde and colleagues.9 The TRAF3 protein product, “TNF Receptor Associated Factor 3”, controls type-1 interferon response,34 and it has been reported that individuals treated with interferon are at high risk to develop depressive symptoms.35 LAMB2 is involved in neuropathic pain and influencing gene expression changes in brain pathways implicated in depression.36
